11 Best Fast Money Stocks to Buy Now

5. Immuneering Corporation (NASDAQ:IMRX)

Upside Potential as of September 29, 2025: 139.88%

Analysts at Mizuho have reaffirmed their ‘Outperform’ rating on Immuneering Corporation (NASDAQ:IMRX), while maintaining a price target of $10, implying a surge of about 43%. This optimism stems from the company’s positive clinical trial outcome for its lead drug candidate.

On Wednesday, Immuneering Corporation (NASDAQ:IMRX) reported modified 9-month survival data from its Phase 2a trial of atebimetinib (atebi), together with updated gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The data, collected from 34 patients, reflected overall survival and progression-free survival results that not only surpassed the traditional standard-of-care treatments, but also the research firm’s own expectations.

What keeps the investor’s interest is the company’s atebimetinib, which has the potential to become a top-tier treatment for first-line pancreatic cancer patients. With the results demonstrating enhanced durability in contrast to the previous 6-month data update from June, we have a good reason to believe in the prospects of the drug, and ultimately Immuneering Corporation (NASDAQ:IMRX).

Immuneering Corporation (NASDAQ:IMRX) is a Massachusetts-based clinical-stage oncology company specializing in treatments targeting broad populations of cancer patients. Founded in 2008, the company is committed to developing innovative medicines.